Apple News Facebook Twitter 新浪微博 Instagram YouTube Wednesday, Oct 21, 2020

60,000 volunteers receive Chinese COVID-19 vaccines in phase-3 trials

(Xinhua)    08:56, October 21, 2020

An exhibitor shows a 3D model of inactivated COVID-19 vaccine antigen to visitors at the booth of SINOVAC in the special area for public health and epidemic prevention in the comprehensive exhibition area of the 2020 China International Fair for Trade in Services (CIFTIS) in Beijing, capital of China, Sept. 5, 2020. (Xinhua/Zhang Yuwei)

BEIJING, Oct. 20 (Xinhua) -- A total of about 60,000 volunteers have been given Chinese COVID-19 vaccines as part of phase-3 clinical trials, with no severe side-effects reported, a Chinese official said on Tuesday.

Four Chinese vaccine candidates have entered international phase-3 clinical trials so far, said Tian Baoguo with the Ministry of Science and Technology at a news conference in Beijing. All trials are progressing well, he said, with initial indications that the vaccines are safe.

According to Tian, the most common adverse reactions in phase-3 clinical trials are pain and swelling at the injection site, followed by fever, both of which are mild.

The two inactivated vaccines developed by China National Biotec Group (CNBG), which is affiliated to Sinopharm, and the Wuhan Institute of Biological Products, have started phase-3 clinical trials in 10 countries, with more than 50,000 volunteers taking part, said Liu Jingzhen, chairman of Sinopharm.

Sinovac Biotech, another vaccine developer, said that the company's partners in Brazil, Indonesia and Turkey have established monitoring systems for adverse reactions in accordance with internationally accepted standards. So far, no severe adverse reactions related to COVID-19 vaccines have been reported.

(For the latest China news, Please follow People's Daily on Twitter and Facebook)
(Web editor: Wen Ying, Liang Jun)

Add your comment

Most Read

Hot News

We Recommend


prev next

Related reading